NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · Real-Time Price · USD
2.200
-0.230 (-9.47%)
Aug 12, 2025, 9:39 AM - Market open

Company Description

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.

The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome.

It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.

NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

NeurAxis, Inc.
NeurAxis logo
CountryUnited States
Founded2011
IPO DateAug 9, 2023
IndustryBiotechnology
SectorHealthcare
Employees21
CEOBrian Carrico

Contact Details

Address:
11611 North Meridian St, Suite 330
Carmel, Indiana 46032
United States
Phone812 689 0791
Websiteneuraxis.com

Stock Details

Ticker SymbolNRXS
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code0001933567
CUSIP Number64134X201
ISIN NumberUS64134X2018
Employer ID45-5079684
SIC Code3845

Key Executives

NamePosition
Brian CarricoPresident, Chief Executive Officer and Director
Timothy Robert HenrichsChief Financial Officer
Dr. Adrian MirandaSenior Vice President of Science and Technology and Chief Medical Officer
Dr. Thomas CarricoChief Regulatory Officer and Compliance and Privacy Officer
Dr. Christopher Robin Brown D.D.S.Founder, Director of Innovation and Director

Latest SEC Filings

DateTypeTitle
Aug 12, 202510-QQuarterly Report
Jul 3, 20258-KCurrent Report
Jul 2, 2025SCHEDULE 13G/AFiling
Jul 1, 2025SCHEDULE 13G/AFiling
Jun 4, 20258-KCurrent Report
May 28, 20258-KCurrent Report
May 22, 20258-KCurrent Report
May 22, 2025424B5Filing
May 21, 20258-KCurrent Report
May 12, 202510-QQuarterly Report